Baeganeun Tablet (Talniplufemate)

Adult dose

Administer 370 mg of talniflumate orally per dose 3 times daily. For severe cases, administer 740 mg per dose. Adjust the dose as appropriate according to age and symptoms.

This medication should be consulted with a doctor or pharmacist if taken by individuals who regularly consume three or more drinks per day, as it may pose a risk of gastrointestinal bleeding. This medication may have effects on the cardiovascular system and may increase the risk of serious cardiovascular diseases such as myocardial infarction or stroke, so individuals with a history of cardiovascular disease or risk factors should be particularly cautious. This medication can cause serious gastrointestinal adverse reactions such as gastrointestinal bleeding, ulcers, and perforation, and older individuals or those with a history of gastrointestinal disease are at greater risk. Individuals with peptic ulcers, allergies to this medication or its components, past allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs, severe liver, kidney, or heart disease, pregnant or breastfeeding women, and those with specific genetic lactose intolerance should not take this medication. Individuals with slightly impaired liver or kidney function, older adults, those taking diuretics, and those who have allergic reactions to dyes included in this medication should use it with caution. During treatment with this medication, various side effects such as nausea, vomiting, diarrhea, abdominal pain, skin rashes, urticaria, dizziness, and kidney problems may occur; therefore, if unusual symptoms arise, consultation with a doctor should be sought immediately. Regular blood tests and liver and kidney function tests are important to check for abnormalities during long-term use. It is recommended not to take this medication with other anti-inflammatory pain relievers, and if you are taking other medications, you must inform your doctor due to potential drug interactions. Especially pregnant women in their late term should not take this medication as it may pose risks to the fetus, and breastfeeding women should also discontinue breastfeeding if taking this medication. This medication should not be administered to children, particularly those aged 12 years or younger. Elderly patients should use the minimum dosage and pay special attention to the occurrence of side effects. This medication should be stored out of the reach of children, and it is safer and better for quality maintenance not to transfer it to another container.

Gastrointestinal bleeding, serious cardiovascular thrombotic reactions, myocardial infarction, stroke, nausea, vomiting, photosensitivity, asthma attack, generalized weakness due to hypotension, hypersensitivity shock, diarrhea, abdominal distension, constipation, dyspepsia, ulcerative stomatitis, abdominal pain, hematemesis, colitis, exacerbation of Crohn's disease, hypertension, tachycardia, chest pain, arrhythmia, palpitations, hypotension, congestive heart failure, edema, hypertension, heart failure, vesicular reactions, Stevens-Johnson syndrome, Lyell syndrome, rash, urticaria, itching, purpura, dizziness, acute renal failure, interstitial nephritis, nephrotic syndrome, fluoride poisoning, abnormal liver tests, thrombocytopenia

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature. Proper storage will help maintain the effectiveness and safety of the medication for a long time.

Appearance

Orange round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle